PRESS RELEASE published on 03/05/2025 at 15:52, 3 months 9 days ago Nomination of Christophe Thurieau as an Independent Member of OPM Board of Directors Oncodesign Precision Medicine appoints Christophe Thurieau, Executive Director Research at Servier, as an independent member of the Board of Directors for a four-year term. Thurieau brings over 35 years of healthcare expertise to OPM Board Of Directors Healthcare Christophe Thurieau Oncodesign Precision Medicine Servier
BRIEF published on 03/05/2025 at 15:52, 3 months 9 days ago Christophe Thurieau rejoint le Conseil d'Administration d'Oncodesign Precision Medicine Biotechnologie Conseil D'administration Nomination Christophe Thurieau Oncodesign Precision Medicine
BRIEF published on 03/05/2025 at 15:52, 3 months 9 days ago Christophe Thurieau joins the Board of Directors of Oncodesign Precision Medicine Board Of Directors Biotechnology Appointment Christophe Thurieau Oncodesign Precision Medicine
PRESS RELEASE published on 03/05/2025 at 15:47, 3 months 9 days ago Nomination of Christophe Thurieau as an Independent Member of OPM Board of Directors Nomination de Christophe Thurieau en tant qu’administrateur indépendant du Conseil d’Administration d’OPM. Christophe Thurieau, expert en Recherche et Développement Pharmaceutique, rejoindra OPM pour un mandat de 4 ans Biopharmaceutique Médecine De Précision Administrateur Indépendant OPM Christophe Thurieau
BRIEF published on 10/15/2024 at 08:05, 7 months 30 days ago OPM-101 Phase 1 Trial Results Presented at UEG Week 2024 Ulcerative Colitis Phase 1 Trial UEG Week 2024 OPM-101 Safety Profile
BRIEF published on 10/15/2024 at 08:05, 7 months 30 days ago Résultats de l'essai de phase 1 OPM-101 présentés à l'UEG Week 2024 Rectocolite Hémorragique Semaine UEG 2024 OPM-101 Essai De Phase 1 Profil De Sécurité
PRESS RELEASE published on 10/15/2024 at 08:00, 7 months 30 days ago Inside Information / Other news releases OPM presents safety & efficacy data on OPM-101, a novel RIPK2 kinase inhibitor, in healthy volunteers at UEG Week 2024 conference, targeting IBD treatment Precision Medicine UEG Week 2024 OPM-101 RIPK2 Kinase Inhibitor IBD Treatment
Published on 06/14/2025 at 16:25, 29 minutes ago New to The Street Episode #671 Airs Tonight on Bloomberg Television at 6:30 PM EST Featuring FLOKI, Arrive AI (NASDAQ: ARAI), Health In Tech (NASDAQ: HIT), Vita Bella, and NRX Pharmaceuticals (NASDAQ: NRXP)
Published on 06/14/2025 at 02:00, 14 hours 54 minutes ago Battery X Metals Validates Provisional Patent Applications Filed with the United States Patent and Trademark Office Through Successful Real-World Trials of Next-Generation Lithium-Ion Battery Rebalancing Machine
Published on 06/14/2025 at 01:05, 15 hours 49 minutes ago Diamcor Receives Section 244 Notice from Tiffany & Co.
Published on 06/13/2025 at 19:10, 21 hours 44 minutes ago Allane Mobility Group records growth in operating business in 2024
Published on 06/13/2025 at 18:47, 22 hours 6 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 06/13/2025 at 18:47, 22 hours 6 minutes ago Funding Circle Holdings plc: HOL-Holdings in Company - AMENDED
Published on 06/13/2025 at 18:42, 22 hours 11 minutes ago Funding Circle Holdings plc: HOL-Holdings in Company - AMENDED
Published on 06/13/2025 at 18:00, 22 hours 54 minutes ago BOA CONCEPT: Mise à disposition des documents préparatoires de l’Assemblée Générale du 26 juin 2025
Published on 06/13/2025 at 18:07, 22 hours 46 minutes ago Déclaration des transactions sur actions propres réalisées du 2 juin au 6 juin 2025
Published on 06/13/2025 at 18:07, 22 hours 46 minutes ago Disclosure of trading in own shares between June 2nd and 6th, 2025
Published on 06/13/2025 at 09:55, 1 day 6 hours ago Déclaration d'actions et de droits de vote au 31.05.2025